Blood test to monitor treatment in metastatic breast cancer
Official title: Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment
Run by Queen's University · NCT05804578 · Data updated 2026-11-12
This study is testing a new blood test to see if it can help women with metastatic breast cancer know sooner if their treatment is working.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | Queen's University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Kingston, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | October 19, 2023 |
| Main results expected | January 2026 |
| Study ends | April 2026 |
| Registry record updated | July 25, 2025 |
| Trial ID | NCT05804578 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult women with a confirmed diagnosis of metastatic breast cancer who are starting a new systemic therapy.
✕Probably not a fit
Patients with exclusive bone metastases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of the mDETECT blood test in monitoring treatment responses in women with metastatic breast cancer. The mDETECT assay utilizes a liquid biopsy approach to detect specific DNA methylation patterns associated with breast cancer, allowing for earlier assessment of treatment efficacy compared to traditional imaging methods. By analyzing circulating tumor DNA from blood samples, the study seeks to provide timely insights into whether a patient's therapy is effective, potentially reducing delays in switching to more effective treatments. The study includes women with measurable metastatic breast cancer who are starting a new systemic therapy regimen.
Why it matters
Potential benefit: If successful, this study could enable earlier detection of treatment responses, leading to improved management of metastatic breast cancer.
How similar studies have gone: Other studies utilizing liquid biopsy approaches have shown promise in monitoring cancer treatment responses, suggesting potential success for this method.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Where it's running
-
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada Recruiting -
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Christopher R Mueller, Ph.D. — Queen's University
- Study coordinator: Christopher R Mueller, Ph.D.
- Email: muellerc@queensu.ca
- Phone: 613-533-6751
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Personalized treatment after endocrine therapy failure in metastatic breast cancer
The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.
-
SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer
This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.
-
SMP-656 in HER2-positive advanced breast cancer after ADC therapy
This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer
This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.